Business Context and Reporting Period
This Form 8-K is filed by MediciNova, Inc. for the reporting period of January 14, 2009. The filing addresses the creation of a direct financial obligation related to the company's auction rate securities portfolio held with UBS AG.
Key Financial Metrics and Obligations
- Debt Facility: Entered into an uncommitted, demand revolving line of credit (the "No Net Cost Loan") with UBS Bank USA.
- Loan Capacity: Up to 75% of the market value of pledged auction rate securities, as determined by UBS Bank.
- Interest Terms: Interest paid on the loan will not exceed interest received on the pledged securities.
- Drawdown: On January 20, 2009, the company borrowed $15,900,000 under this agreement.
- Liquidity Context: The facility was established to provide liquidity following a November 5, 2008, settlement with UBS regarding auction rate securities.
Material Changes and Settlement Details
The filing details a settlement reached on November 5, 2008, wherein UBS issued "Rights" to MediciNova, allowing the company to sell its auction rate securities at par value between June 30, 2010, and July 2, 2012. In exchange, MediciNova released UBS from most claims regarding the marketing and sale of these securities and granted UBS discretionary rights to dispose of the securities, provided MediciNova receives par value.
Outlook, Risks, and Contingencies
- Call Risk: The credit line is uncommitted; UBS Bank may demand full or partial payment at any time without cause.
- Termination Risk: UBS Bank may terminate and cancel the loan at its sole discretion.
- Collateral Requirements: All advances are subject to collateral maintenance requirements.
- Contingency Protection: If UBS Bank exercises its right of demand, UBS Financial Services Inc. or an affiliate must provide alternative financing on substantially the same terms as soon as reasonably possible.
Investor Verification Checklist
- Verify the current market value of the auction rate securities pledged as collateral to determine the remaining borrowing capacity.
- Confirm the status of the $15,900,000 drawdown and any subsequent repayments or additional advances.
- Review the "Important Notice on Interest Rates and Payments" (Exhibit 10.4) to understand specific interest rate mechanics.
- Monitor for any notices of demand for payment or termination of the credit line by UBS Bank.
- Assess the timeline for the "Rights" to sell securities at par value (June 2010 to July 2012) relative to the company's liquidity needs.